Coverage of dose 1, series completion, and timely dose 1 for Hib vaccine and PCV by sex, birth year and residency status of Shanghai children, 2012.Abram L. WagnerXiaodong SunJoLynn P. MontgomeryZhuoying HuangMatthew L. Boulton
Of interest, the difference between vaccine groups in the overall prevalence of ANSP NP colonization was generally more pronounced at ages 13–24 months than after the primary series (ages 7 and 12 months); however, changes were less pronounced for NP colonization by TMP-SMZ–nonsusceptible ...
Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vacci... This study was conducted to evaluate the effect of a reduced-dose 7-valent pneumococcal conjugate vaccine (PCV) primary series followed by a 23...
[10]Palmu AA, et al. “Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine against invasive pneumococcal disease: a cluster randomized trial” Lancet 2012; published online November 16, 2012 [11]Domingues,C et al .Effectiveness of ten valent pneumococcal c...
Oxidative stress plays an important role in the pathogenesis of virus infection and antioxidants are becoming promising candidates as therapeutic agents. This study is designed to investigate the effect of total flavonoids of Spatholobus suberectus
Differences between demographic groups in the coverage of dose 1, timely dose 1, and series completion for Hib vaccine and PCV in Shanghai children, 2012.Abram L. WagnerXiaodong SunJoLynn P. MontgomeryZhuoying HuangMatthew L. Boulton
Pneumococcal conjugate vaccines (PCV) have reduced invasive pneumococcal disease (IPD) (see other PSERENADE abstract), of which > 70% was vaccine-type pre-PCV. We described the serotype (ST) distribution of remaining IPD in countries with mature infant PCV10/13 programs. METHODS. IPD ST ...
8 Annual PCV uptake estimates provided by the surveillance site for the primary series plus the booster dose by 23 months of age, excluding year of vaccine rollout. 9 Recommended for high-risk populations only but had substantial (≥50% annually) private market uptake among the general ...